Sarcoidosis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Sarcoidosis is a rare inflammatory disease that causes the formation of granulomas—small lumps or nodules. Although it primarily affects the lungs, it can involve multiple organs, including the eyes, skin, liver, kidneys, brain, and heart. Sarcoidosis has no cure, and its treatment depends on the severity of symptoms and the affected organs. Oral corticosteroids, such as prednisone, are the first-line treatment for sarcoidosis. When corticosteroids are not effective or cause side effects, immunosuppressive agents like methotrexate, azathioprine, and leflunomide are usually prescribed. Tumor necrosis factor (TNF) inhibitors such as infliximab and adalimumab are used as third-line therapy. Several therapies are in the pipeline for sarcoidosis, including efzofitimod (aTyr Pharma), XTMAB-16 (Xentria), and namilumab (Kinevant Sciences). This report offers insight from real-world claims data into prescribing trends in sarcoidosis to help developers better understand current treatment and define the market niche for emerging products.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed sarcoidosis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed sarcoidosis patients?
  • How has biological therapy been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of sarcoidosis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of sarcoidosis patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Mallinckrodt, AbbVie, Janssen Biotech

Key drugs: Acthar gel, adalimumab, infliximab, oral corticosteroids, oral methotrexate

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

launch Related Market Assessment Reports